Promoter methylation status of multiple genes in uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 10, 2007, Pages 4403-4406

  Merhavi, Efrat ^a,b   Cohen, Yoram ^c   Avraham, Bat Chen R ^a,b   Frenkel, Shahar ^d   Chowers, Itay ^d   Pe'er, Jacob ^d   Goldenberg Cohen, Nitza ^a,e,f  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^f RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BISULFITE; DEATH ASSOCIATED PROTEIN KINASE; GENE PRODUCT; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NEUROGENIN 1; PROTEIN CACNA1G; PROTEIN RAR B2; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS PROTEIN; SOMATOMEDIN B; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; DNA; TUMOR PROTEIN;

ARTICLE; CANCER GENETICS; CARCINOGENESIS; CHEMICAL MODIFICATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE INACTIVATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UVEA MELANOMA; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; MELANOMA; PATHOLOGY; TUMOR GENE; UVEA TUMOR;

CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; GENE SILENCING; GENES, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; NEOPLASM PROTEINS; PHENOTYPE; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UVEAL NEOPLASMS;

EID: 35748945427     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0272     Document Type: Article

References (27)

1. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347:1222-1225.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
3. Soufir N, Bressac-de Paillerets B, Desjardins L, et al. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. Br J Cancer. 2000;82(4):818-822.
4. Rootman J, Gallagher RP. Color as a risk factor in iris melanoma. Am J Ophthalmol. 1984;98(5):558-561.
5. Tucker MA, Shields JA, Hartge P, Augsburger J, Hoover RN, Fraumeni JF Jr. Sunlight exposure as risk factor for intraocular malignant melanoma. N Engl J Med. 1985;313(13):789-792.
6. Cohen Y, Goldenberg-Cohen N, Parrella P, et al. Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(7):2876-2878.
7. Hearle N, Damato BE, Humphreys J, et al. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(2):458-462.
8. Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1-2):73-87.
9. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21(2):163-167.
10. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene. 2004;23(22):4014-4022.
11. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006;55(7):1000-1006.
12. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787-793.
13. van der Velden PA, Metzelaar-Blok JA, Bergman W, et al. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res. 2001;61(13):5303-5306.
14. Edmunds SC, Kelsell DP, Hungerford JL, Cree IA. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2002;43(9):2845-2851.
15. van der Velden PA, Zuidervaart W, Hurks MH, et al. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer. 2003;106(4):472-479.
16. Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005;92(11):2032-2038.
17. Maat W, van der Velden PA, Out-Luiting C, et al. Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci. 2007;48(2):486-490.
18. Merbs SL, Sidransky D. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. Invest Ophthalmol Vis Sci. 1999;40(3):779-783.
19. Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res. 2003;9(8):2981-2984.
20. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28(8):E32.
21. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the RASSF1A gene in human cancers. Biol Chem. 2002;383(6):907-914.
22. Yan PS, Shi H, Rahmatpanah F, et al. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res. 2003;63(19):6178-6186.
23. Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res. 2003;9(10):3635-3640.
24. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315-319.
25. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 2003;63(7):1639-1643.
26. Parrella P, Fazio VM, Gallo AP, Sidransky D, Merbs SL. Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. Cancer Res. 2003;63(23):8507-8510.
27. Imreh S, Klein G, Zabarovsky ER. Search for unknown tumor-antagonizing genes. Genes Chromosomes Cancer. 2003;38(4):307-321.